Browse studies

Find your next paid study

70 recruiting studies matching your filters

Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic Dermatitis

Background: \- Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S. aureus bacteria. Researchers want to study…

EczemaDermatitisSkin Diseases, Genetic+2 more

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NCT01631617

Phase 1

A Pilot Study to Evaluate the Safety and Tolerability of Baricitinib in Patients With Job s Syndrome With Lupus-like Disease and/or Atopic Dermatitis

Background: Autosomal dominant hyper-IgE syndrome (HIES), also called Job syndrome, is a genetic disorder that affects the immune system. It can cause skin an…

Hyper IgE Syndrome From STAT3 MutationJob s SyndromeHIES+2 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Institute of Allergy and Infectious Diseases (NIAID)NCT07262983

Phase 3

A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with moderate-to-se…

Atopic DermatitisEczema

Estimated

~$50 – $2,250

Actual pay is set by the research site.

Eli Lilly and CompanyNCT05735483

Phase 1

A Phase 1a/1b, Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 in Healthy Volunteers and Subjects With Moderate to Severe Atopic Dermatitis.

This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the …

Atopic Dermatitis (AD)Eczema

Estimated

~$500 – $10,500

Actual pay is set by the research site.

Arcutis Biotherapeutics, Inc.NCT07453602

Observational

Outcomes of a Digital Mindfulness Meditation App-Based Intervention in Adolescents With Moderate to Severe Atopic Dermatitis (MIND-AD)

Atopic dermatitis is well reported to have a significant impact on well-being in adolescents with atopic dermatitis, without clear recommendations for interven…

Atopic DermatitisEczema

Estimated

~$10 – $750

Actual pay is set by the research site.

Weill Medical College of Cornell UniversityNCT07746427

Phase 3

A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, ACTIVE- AND PLACEBO-CONTROLLED PHASE 3 MONOTHERAPY STUDY WITH MAINTENANCE PERIOD TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to seve…

Atopic Dermatitis

Estimated

~$50 – $2,250

Actual pay is set by the research site.

PfizerNCT07783425

Phase 2

A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777

This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-sever…

Atopic Dermatitis

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Apogee Therapeutics, Inc.NCT07003425

Phase 3

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 year…

Moderate-to-Severe Atopic Dermatitis

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Nektar TherapeuticsNCT07690371

Evaluation of a Non-Invasive Device for Early Detection of Flares in Adults and Adolescents With Atopic Dermatitis

This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 yea…

Atopic Dermatitis

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Castle Biosciences IncorporatedNCT07645820

Phase 4

Utilization of a Cutaneous Therapy In Situ Microdevice

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and …

PsoriasisAtopic Dermatitis

Estimated

~$25 – $900

Actual pay is set by the research site.

University of California, San FranciscoNCT07352566

Metabolic Profiling of Immune Responses in Immune-Mediated Diseases

Background: The immune system is the part of the body that fights infection. Some people have immune deficiencies that cause skin rashes, make them get sick o…

Primary ImmunodeficiencyPsoriasisAtopic Dermatitis+1 more

Estimated

~$10 – $675

Actual pay is set by the research site.

National Institute of Allergy and Infectious Diseases (NIAID)NCT04864886

Phase 2

A Long-term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous IMG-007 in Participants of a Previous IMG-007 Moderate-To-Severe Atopic Dermatitis Clinical Trial

The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis …

Atopic DermatitisAtopic Dermatitis EczemaEczema

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Inmagene LLCNCT07734415